TY - JOUR
T1 - Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies
T2 - a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology
AU - Pudil, Radek
AU - Mueller, Christian
AU - Čelutkienė, Jelena
AU - Henriksen, Peter A.
AU - Lenihan, Dan
AU - Dent, Susan
AU - Barac, Ana
AU - Stanway, Susanna
AU - Moslehi, Javid
AU - Suter, Thomas M.
AU - Ky, Bonnie
AU - Štěrba, Martin
AU - Cardinale, Daniela
AU - Cohen-Solal, Alain
AU - Tocchetti, Carlo Gabriele
AU - Farmakis, Dimitrios
AU - Bergler-Klein, Jutta
AU - Anker, Markus S.
AU - Von Haehling, Stephan
AU - Belenkov, Yury
AU - Iakobishvili, Zaza
AU - Maack, Christoph
AU - Ciardiello, Fortunato
AU - Ruschitzka, Frank
AU - Coats, Andrew J.S.
AU - Seferovic, Petar
AU - Lainscak, Mitja
AU - Piepoli, Massimo F.
AU - Chioncel, Ovidiu
AU - Bax, Jereon
AU - Hulot, Jean Sebastien
AU - Skouri, Hadi
AU - Hägler-Laube, Eva Simona
AU - Asteggiano, Riccardo
AU - Fernandez, Teresa Lopez
AU - de Boer, Rudolf A.
AU - Lyon, Alexander R.
N1 - Publisher Copyright:
© 2020 European Society of Cardiology
PY - 2020/11
Y1 - 2020/11
N2 - Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases in cardiac biomarkers including cardiac troponin and natriuretic peptides can be used to guide initiation of cardioprotective treatments for cancer patients during treatment and to monitor the response to cardioprotective treatments, and they also offer prognostic value. This position statement examines the role of cardiac biomarkers in the management of cancer patients. The Cardio-Oncology Study Group of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) in collaboration with the Cardio-Oncology Council of the ESC have evaluated the current evidence for the role of cardiovascular biomarkers in cancer patients before, during and after cardiotoxic cancer therapies. The characteristics of the main two biomarkers troponin and natriuretic peptides are discussed, the link to the mechanisms of cardiovascular toxicity, and the evidence for their clinical use in surveillance during and after anthracycline chemotherapy, trastuzumab and HER2-targeted therapies, vascular endothelial growth factor inhibitors, proteasome inhibitors, immune checkpoint inhibitors, cyclophosphamide and radiotherapy. Novel surveillance clinical pathways integrating cardiac biomarkers for cancer patients receiving anthracycline chemotherapy or trastuzumab biomarkers are presented and future direction in cardio-oncology biomarker research is discussed.
AB - Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases in cardiac biomarkers including cardiac troponin and natriuretic peptides can be used to guide initiation of cardioprotective treatments for cancer patients during treatment and to monitor the response to cardioprotective treatments, and they also offer prognostic value. This position statement examines the role of cardiac biomarkers in the management of cancer patients. The Cardio-Oncology Study Group of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) in collaboration with the Cardio-Oncology Council of the ESC have evaluated the current evidence for the role of cardiovascular biomarkers in cancer patients before, during and after cardiotoxic cancer therapies. The characteristics of the main two biomarkers troponin and natriuretic peptides are discussed, the link to the mechanisms of cardiovascular toxicity, and the evidence for their clinical use in surveillance during and after anthracycline chemotherapy, trastuzumab and HER2-targeted therapies, vascular endothelial growth factor inhibitors, proteasome inhibitors, immune checkpoint inhibitors, cyclophosphamide and radiotherapy. Novel surveillance clinical pathways integrating cardiac biomarkers for cancer patients receiving anthracycline chemotherapy or trastuzumab biomarkers are presented and future direction in cardio-oncology biomarker research is discussed.
UR - http://www.scopus.com/inward/record.url?scp=85092942359&partnerID=8YFLogxK
U2 - 10.1002/ejhf.2017
DO - 10.1002/ejhf.2017
M3 - Article
C2 - 33006257
AN - SCOPUS:85092942359
SN - 1388-9842
VL - 22
SP - 1966
EP - 1983
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
IS - 11
ER -